Evidence map›Paper›PMID 41458604›Full record

ArticleFrontiers in oncology2025

Leucine-rich repeat neuronal 1 as a prognostic indicator and functional modulator in breast cancer.

Jiaxin Wang, Xiqian Zhou, Ding Ping, Meiling Lu, Yue Zhang, Hongming Song, Junyong Zhao, Dengfeng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Cross-tissue immune profiling of APOE ε4 reveals early dysregulation in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaxin Wang *Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Institute of Breast Disease, Nanjing Medical University, Shanghai, China.
Xiqian Zhou *Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Institute of Breast Disease, Nanjing Medical University, Shanghai, China.
Ding Ping *Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Institute of Breast Disease, Nanjing Medical University, Shanghai, China.
Meiling LuDepartment of Central Laboratory, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China.
Yue ZhangDepartment of Central Laboratory, Shanghai Tenth People's Hospital of Tongji University, School of Medicine, Tongji University, Shanghai, China.
Hongming SongBreast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Junyong ZhaoDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Institute of Breast Disease, Nanjing Medical University, Shanghai, China.
Dengfeng LiDepartment of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Institute of Breast Disease, Nanjing Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advanced breast cancer remains a major therapeutic challenge with high mortality rates. While leucine-rich repeat (LRR) proteins play roles in various cancers including breast cancer, their specific functions are still underexplored. This study aimed to address this research gap by focusing on the leucine-rich repeat neuronal (LRRN) family, with the goal of clarifying their expression, clinical value, and prognostic significance in breast cancer-particularly LRRN1 in advanced cases. Methods: To investigate the expression of LRRN family members in breast cancer, this study utilized public databases including TCGA-BRCA, GEO, and UALCAN. It further analyzed the clinical value of these LRRN family members and specifically identified the prognostic significance of LRRN1 in advanced breast cancer cases. Functional assays (assessing proliferative, migratory, and invasive capabilities of cancer cells) were conducted to evaluate LRRN1's biological effects. Additionally, WGCNA, GO analysis, KEGG analysis, and western blotting were employed to verify the molecular pathways impacted by LRRN1. Results: LRRN1 was found to be significantly downregulated in advanced breast cancer tissues compared to normal tissues (p < 0.001). Moreover, high LRRN1 expression correlated with better disease-free survival (DFS) in advanced breast cancer patients (HR=0.755, 95% CI: 0.617-0.923, p < 0.01). Functional assays revealed that LRRN1 suppresses cancer cell metastasis (without affecting cancer cell proliferation) (p<0.01). Results from WGCNA, GO, KEGG analyses, and western blot confirmed that LRRN1 impacts the Wnt signaling pathway (p<0.05). Additionally, LRRN1 may activate γδ T cells and resting dendritic cells, regulate the M1/M2 macrophage balance in the tumor microenvironment (p<0.001), and mediate the efficacy of certain tyrosine kinase inhibitors (TKIs) (p<0.001). Discussion: Overall, LRRN1 emerges as a promising prognostic indicator and functional mediator in advanced breast cancer. It potentially exerts its effects by influencing the Wnt signaling pathway and regulating immunotherapy responses. However, the specific mechanisms underlying LRRN1's actions, as well as its potential clinical applications, still require further exploration to fully translate these findings into clinical practice for advanced breast cancer treatment.

Indexed as

breast cancerimmunotherapyleucine-rich repeat neuronal 1metastasisWnt signals

Identifiers

PMID41458604
PMCPMC12738307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.